About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« United Cannabis Corp. v. Pure Hemp Collective Inc. (D. Colo. 2019) | Main | JMLS Program on ITC Practice »

April 26, 2019


An example of the negative media coverage of the pharma industry in the U.S.: Joe Nocera: "Why Big Pharma Is Winning the Drug Price Wars" (Bloomberg) [That report seems to even suggest marketing obfuscation and/or antitrust issues?]
Of patent concern, this kind of publicity seems likely to reduce the traditional pro-patent-law lobbying effectiveness of this industry.

Mr. Morgan,

Another example of "pro-patent" lobbying that reduces rather than benefits the overall view of patents can be seen in the Pharma efforts to eliminate or control natural secondary markets in the cross-border sense AFTER the patent holder has already achieved their benefit of a first sale - and the Big Pharma attempts to play a geographic sales game, which only make the average US citizen a de facto supporter of Big Pharma profit levels and artificially reduced prices in the foreign markets.

This aspect DOES circle back into the thread above, as Big Pharma allows itself to be negotiated INTO those "regulat[ed] drug prices by reference to an international index based on government-negotiated drug prices abroad" POSSIBILITY as is noted on a new post at: https://www.ipwatchdog.com/2019/04/28/accelerating-generic-entry-proven-solution-problem-prescription-drug-pricing/id=108586/

The comments to this entry are closed.

May 2024

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31